Markets & Deals
Sino Biopharmaceutical Enters Exclusive Global Licensing Agreement with Sanofi for First-in-Class JAK/ROCK Inhibitor Rovadicitinib
2026-03-04
U.S. and Taiwan Finalize Reciprocal Trade Deal, Locking in 15% Tariff Rate and $85 Billion Purchase Commitment
2026-02-13
[Illustrations] Selective Capital, Targeted Deals, and a Tightened Public-Market Bar: How 2026 Is Shaping M&A and IPOs
2026-02-09
Biotech IPO Market Thaws: Eikon, Agomab, SpyGlass and Veradermics Lead Billion-Dollar Revival
2026-02-09
[Illustrations] 2026 Obesity’s Second Wave: Market Fragmentation Starts to Challenge First-Generation Dominance
2026-02-05
[Illustrations] 2026 Biopharma’s “Clearing Year”: IRA, BIOSECURE, and the Phase 3 Threshold Becoming the True Litmus Test
2026-02-05
Moderna and Recordati Form Strategic Alliance to Commercialize mRNA Therapy for Propionic Acidemia
2026-02-04
AstraZeneca Pledges $15 Billion China Investment and Signs Up to $18.5 Billion CSPC Obesity Deal
2026-02-02
Why System Integration Is Eclipsing the Chip War: AI’s Energy, Infrastructure, and Sovereignty Bottleneck
2026-01-28
LATEST
Gut Microbiome Composition Predicts Long-term Cardiometabolic Health Outcomes in Diverse Urban Populations
2026-03-12
NVIDIA Ahead of GTC 2026: Markets Focus on Data Center Strength, PC Expansion, and the Next Technical Breakout
2026-03-12
Global and APAC Biopharma Watch: Capital Raising, Clinical Expansion, and Industry Moves in Focus
2026-03-12
EVENT
2026-04-09
4th Cell & Gene Therapy Innovation & Access Congress: Asia (Media Partnership)
Seoul, South Korea



